All In Biotech

Drug Trial Radar · NCT05292196

A Phase II Clinical Trial of TQC3721 Suspension for Inhalation

A Randomized, Double-blind, Placebo-parallel, Multicenter Phase II Trial of the Efficacy and Safety of TQC3721 Suspension for Inhalation in the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease

Last checked: Nov 20, 2026Latest source record: Apr 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

59

Actual

Start

May 20, 2022

Primary completion

Jan 11, 2023

Study completion Dec 5, 2023

Sponsor

Sponsor type
Industry
First posted
Mar 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

TQC3721 suspension for inhalation is a PDE3/4 inhibitor developed by Chia Tai Tianqing Pharmaceutical Group Co., LTD., which can simultaneously achieve bronchial smooth muscle relaxation and anti-inflammatory effects. This is a randomized, double-blind, placebo-parallel, phase II trial of the efficacy and safety of inhaled TQC3721 suspension/placebo at different doses in patients with moderate to severe chronic obstructive pulmonary disease. Objective To evaluate the efficacy, safety and tolerability of TQC3721 inhalation suspension in the treatment of moderate to severe Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • TQC3721 suspension for inhalationDrug

    TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor

  • TQC3721 suspension placebo for inhalationDrug

    TQC3721 suspension for inhalation is Dual PDE3/4 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The peak of Forced Expiratory Volume(FEV1)Time frame: From the enrollment of the subjects to four weeks after administration

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Chongqing Medical University

    Chongqing, Chongqing Municipality, China

  • Gansu Provincial Hospital

    Lanzhou, Gansu, China

  • The Affiliated Hospital of Guangdong Medical University

    Zhanjiang, Guangdong, China

  • The Fourth Affiliated Hospital of Harbin Medical University

    Harbin, Heilongjiang, China

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China

  • Northern Jiangsu People's Hospital

    Yangzhou, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jianxi, China

  • The First Hospital of Jilin University

    Changchun, Jilin, China

  • The First Affiliated Hospital of China Medical University

    Shenyang, Liaoning, China

  • West China Hospital of Sichuan University

    Chengdu, Sichuan, China

  • Mianyang Central Hospital

    Mianyang, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.